Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:4.1.1.6 (CAD)
 4,420 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Event-related P300 potentials that closely reflect cognitive brain functions show significant age-related latency prolongations. This aging-P300 interaction can best be approximated by third-order polynomial regressions. To delineate the clinical impact this special kind of regression function may have on detecting early cognitive dysfunction, we applied visual P300 potential data of healthy subjects (n = 344; age range, 18-98 years) to nondemented patients with either (i) chronic liver disease (n = 104; age range, 19-74 years) or (ii) cerebral arteriosclerosis (n = 80; age range, 38-80 years). As compared with linear regressions, third-order polynomial regressions for the age-related changes in P300 potential latencies showed a smaller latency increase during middle age, with an accelerating latency prolongation from age 60 onward. In patients with liver cirrhosis, third-order polynomial regressions yielded a rate of abnormal P300 potential latencies exceeding that of linear regressions absolutely by 17-21%, and relatively by 67-71%. Although the rate of P300 abnormalities was much lower in the CAD patients with either regression model, the relative increase in P300 abnormalities due to third-order polynomial regressions was 40-112.5%. In conclusion, normal data for the latencies of P300 potentials based on third-order polynomial regressions result in a higher sensitivity of P300 potentials for detecting early cognitive dysfunction. This gain in diagnostically important information is not offset by a loss in specificity, and may depend on the kind as well as stage of the disease, the age distribution of the patients and the degree of the P300 potential abnormalities.
 ...
PMID:The impact of age-related changes in event-related P300 potentials on detecting early cognitive dysfunction. 1537 98

Dyslipidemia is a primary, major risk factor for coronary artery disease CAD. The prevalence of dyslipidemia had decreased over the past 30 years, which may in part be explained by the steady increase in the use of lipid-lowering drug therapy, especially statins. Cardiovascular risk has been shown to be greater in liver disease (20% in the liver cirrhosis vs. 12% in the general population), where statins can play an important role as a primary and secondary prevention for CAD. Given patients with chronic liver disease, especially liver cirrhosis are at risk of decreased hepatic clearance, there is concern that this patient population may be at higher risk for complications from statin therapy. Several retrospective studies showed that statin use in chronic liver disease and cirrhosis is safe, and even it was associated with lower mortality and lower rate of hepatic decompensation. This review discusses the safety and the different mechanisms where statins can decrease the rate of complications in liver cirrhosis, including portal hypertension, sepsis and the incidence of hepatocellular carcinoma.
...
PMID:The Safety and Benefit of Statins in Liver Cirrhosis: a Review. 2660 51